P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC
A. Horne(University of Manchester), A. Greystoke(University of Newcastle Australia), Hao Yang(Cambridge University Hospitals NHS Foundation Trust), A.J. Chalmers(University of Glasgow), J. Kendall(University of Leeds), Stephen Harrow(Beatson West of Scotland Cancer Centre), M. Hatton(Weston Park Cancer Centre), Crispin T. Hiley(The Francis Crick Institute), J.B. Oughton(University of Leeds), Vicky M. Coyle(Queen's University Belfast), Sarah Brown(University of Leeds), F. Walker(University of Leeds), C. Faivre-Finn(University of Manchester), Adam Hassani(Freeman Hospital), Paul Shaw(Velindre Cancer Centre), K. Franks(Leeds Teaching Hospitals NHS Trust)
Cited by 2
Related Papers
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k